title: Use of tazarotene foam for the treatment of acne vulgaris.
abstract: Acne vulgaris is a common inflammatory chronic disease of the pilosebaceous unit. It often requires long-term treatment, resulting in increased demand for topical medications that are popular with patients in order to achieve long-term compliance. Tazarotene foam 0.1% is a novel formulation of tazarotene. We review efficacy and tolerability studies of the new formulation, and suggest a possible place for the product in the management of acne vulgaris.
authors.affiliation: Second Department of Dermatology and Venereology, Attikon Hospital, University of Athens Medical School, Athens, Greece.
authors.forename: Stamatis
authors.initials: S
authors.lastname: Gregoriou
authors.affiliation: Second Department of Dermatology and Venereology, Attikon Hospital, University of Athens Medical School, Athens, Greece.
authors.forename: Eleftheria
authors.initials: E
authors.lastname: Kritsotaki
authors.affiliation: Second Department of Dermatology and Venereology, Attikon Hospital, University of Athens Medical School, Athens, Greece.
authors.forename: Alexandros
authors.initials: A
authors.lastname: Katoulis
authors.affiliation: Second Department of Dermatology and Venereology, Attikon Hospital, University of Athens Medical School, Athens, Greece.
authors.forename: Dimitris
authors.initials: D
authors.lastname: Rigopoulos
keywords: efficacy; retinoids; safety; tolerability